NCT04713878

Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia

Completed NA Last updated 20 January 2021

What this trial tests

NA trial testing Mesenchymal stem cells in Coronavirus Disease 2019 (COVID-19) Pneumonia in 21 participants. Completed in 15 July 2020.

Timeline

8 May 2020

Primary endpoint
30 June 2020

15 July 2020

Quick facts

Lead sponsor	Kanuni Sultan Suleyman Training and Research Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	8 May 2020
Primary completion	30 June 2020
Estimated completion	15 July 2020
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

• Mesenchymal stem cells — full drug profile →

Conditions studied

• Coronavirus Disease 2019 (COVID-19) Pneumonia — all drugs for Coronavirus Disease 2019 (COVID-19) Pneumonia →

Sponsor

Kanuni Sultan Suleyman Training and Research Hospital

Who can join

Adults 18 to 90, any sex, with Coronavirus Disease 2019 (COVID-19) Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Due to the cytokine storm that develops as a result of Coronavirus Disease 2019 (COVID-19) infection, some patients hospitalization to intensive care cause of pneumonia, Acute Respiratory Distress Syndrome (ARDS) and multiple organ failure. Mortality is higher in treatment-resistant cases.

Purpose of this study:

1. Providing immune modulation by Stem Cell Transplantation and reducing the damage caused by cytokine storm to tissues and organs,
2. Correcting immunosuppression and fight against COVID-19 virus by editing B and T cells,
3. It is to accelerate healing in organ damage by increasing growth factors through mesenchymal stem cells.

Primary outcome: Improvement of clinical symptoms, reduction of cytokine storm Secondary outcome: Recovery of patients; from mechanical ventilation

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Clinical Trials Based on Mesenchymal Stromal Cells are Exponentially Increasing: Where are We in Recent Years?
   Galderisi U, Peluso G, Di Bernardo G. · · 2022 · cited 175× · PMID 34398443 · DOI 10.1007/s12015-021-10231-w
2. MSCs vs. iPSCs: Potential in therapeutic applications.
   Thanaskody K, Jusop AS, Tye GJ, Wan Kamarul Zaman WS, et al · · 2022 · cited 59× · PMID 36407112 · DOI 10.3389/fcell.2022.1005926
3. Mesenchymal stem cells and their derived exosomes to combat Covid-19.
   Yousefi Dehbidi M, Goodarzi N, Azhdari MH, Doroudian M. · · 2022 · cited 41× · PMID 34363275 · DOI 10.1002/rmv.2281
4. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications.
   Chen L, Qu J, Kalyani FS, Zhang Q, et al · · 2022 · cited 31× · PMID 35187617 · DOI 10.1007/s00018-021-04096-y
5. Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities.
   Moradinasab S, Pourbagheri-Sigaroodi A, Zafari P, Ghaffari SH, et al · · 2021 · cited 27× · PMID 33932694 · DOI 10.1016/j.intimp.2021.107694
6. Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study.
   Dauletova M, Hafsan H, Mahhengam N, Zekiy AO, et al · · 2021 · cited 26× · PMID 33684527 · DOI 10.1016/j.clim.2021.108712
7. Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?
   da Silva KN, Gobatto ALN, Costa-Ferro ZSM, Cavalcante BRR, et al · · 2021 · cited 19× · PMID 34315546 · DOI 10.1186/s13287-021-02502-7
8. Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19.
   Li JP, Wu KH, Chao WR, Lee YJ, et al · · 2022 · cited 16× · PMID 35897770 · DOI 10.3390/ijms23158196